This case series highlights the occurrence of immune thrombocytopenia (TP) following PD-1 inhibitor therapy and underscores the dual challenges of managing immunotherapy-induced adverse events and implementing precision nursing care in clinical practice. This evidence concerns the gene PDCD1 and autoimmune thrombocytopenic purpura.